Sciety’s portfolio company Capitainer, a Swedish medtech company that develops intelligent solutions for self-sampling of blood and plasma, has received a SEK 30 million investment from We Venture Capital, the venture capital arm of the globally renowned Werfen Group. This strategic investment marks a milestone in Capitainer’s journey towards becoming the leading provider of self-sampling solutions.
We Venture Capital, the venture capital arm of Werfen Group, specialises in empowering innovative companies at the forefront of diagnostic technology. This investment aligns with their mission of transforming patient-oriented diagnostic solutions. Sciety played an important role in connecting Capitainer and We Venture Capital, and assisting Capitainer in negotiating the terms of the investment. This exemplifies Sciety’s proactive and significant contributions to the growth and success of its portfolio companies.
This funding will fuel Capitainer’s expansion efforts, including scaling up production capacity, enhancing sales and marketing strategies, and launching new products. The investment will be administered in two phases: an initial SEK 15 million before the end of this year, followed by an additional SEK 15 million a year later, contingent upon Capitainer achieving specific milestones.
Alongside the substantial investment from We Venture Capital, Sciety has further reinforced its commitment to Capitainer by participating in this funding round. This collaborative investment effort underscores the confidence in Capitainer’s vision and potential and accentuates Sciety’s role in facilitating this investment.
“We are very impressed by the product performance and what the Capitainer team has achieved the last few years. The product portfolio is disruptive and innovative and demonstrates very solid data. We look forward to supporting Capitainer on their future journey,” says Louise Warme, head of We Venture Capital.
Andreas Lindblom, Managing Partner at Sciety, comments: “Apart from strengthening the company financially, we are convinced that the investment from We Venture Capital will result in synergies which also will strengthen the company strategically in its work to position itself as a leading player in the self-sampling market.”
Christopher Aulin, CEO at Capitainer, adds: “Securing this investment from We Venture Capital, an industry leader, represents a significant endorsement and a strategic collaboration for Capitainer. Facilitated by our long-term partner Sciety, this accelerates our expansion, underscores our innovative approach and boosts our efforts in the EU and US markets at a crucial time of growth.”
This substantial investment will not only fuel Capitainer’s expansion efforts by scaling up production capacity, enhancing sales and marketing strategies, and launching new products but also marks the beginning of an investment relationship that could open doors to new collaborations and customer segments.
Contact
Andreas Lindblom, Managing Partner, Sciety: andreas.lindblom@sciety.se, phone 070-375 73 73
Christopher Aulin, CEO, Capitainer: christopher.aulin@capitainer.com, phone 070-897 75 77
About Capitainer
Capitainer AB is a Swedish MedTech company that develops and sells patient-centric solutions for self-sampling of blood, plasma, and urine. Founded in 2016, Capitainer has developed unique technologies for collecting and drying exact volumes of fluid within easy-to-use sampling cards. These cards may be sent as standard post to relevant testing laboratories, thus bypassing the need for cold chain logistics and specialised packaging. Capitainer’s products are market-leading with respect to precision and accuracy, with demonstrated equal performance to established pipetting methods. The products are applicable within several market segments, including but not limited to, clinical biomarkers, therapeutic drug monitoring, genomics, drug abuse and doping testing, and R&D and clinical studies.
About Sciety
Sciety is a leading investment company, committed to supporting the growth of innovative life science and health tech companies in the Nordic region. We invest alongside Sciety Venture Partners, comprising family offices and private investors, as well as venture capital firms. Our mission is to enable the full potential of life science innovations, helping to bring breakthroughs in healthcare to people all over the world. For more information, please visit www.sciety.com and follow us on LinkedIn.
Tags:
